MooreRD, SmithCR, LietmanPS.Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis1984; 149: 23–30.
2.
ChunHG, Leyland-JonesBR, CarykSM, HothDF.Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep1986; 70: 1225–8.
3.
CohenRB, AbdallahJM, GrayJR, FossF.Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med1993; 118: 114–6.
4.
HochsterHS, KimK, GreenMD, MannRB, NeimanRS, OkenMMActivity of fludarabine in previously-treated non-Hodgkin's low-grade lymphoma. Results of an Eastern Cooperative Oncology Group Study. J Clin Oncol1992; 10: 28–32.
5.
KeatingMJ, KantarjianH, TalpazM, RedmanJ, KollerC, BarlogieBFludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood1989; 74: 19–25.
